StoxGranules India vs Syngene International: share price & financials comparison
NSE: GRANULES vs SYNGENE · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Granules India vs Syngene International at a glance
Granules India (GRANULES) has a market capitalisation of ₹22,182 Cr, against ₹17,936 Cr for Syngene International (SYNGENE). Over the past year Granules India has returned +43.2%, compared with -31.3% for Syngene International. On valuation, Granules India trades at a lower P/E of 31.1 versus 469.5. Granules India earns a higher return on equity (10.9% vs 0.8%). Granules India comes out ahead on size, valuation, profitability, momentum and technicals. Syngene International comes out ahead on financial health. Across the scored metrics below, Granules India leads on 13 and Syngene International on 4. On StoxGud's 10-point checklist, Granules India scores 8/10 and Syngene International scores 3/10.
| Metric | Granules India | Syngene International |
|---|---|---|
| Size | ||
| Market cap | ₹22,182 Cr | ₹17,936 Cr |
| Revenue (latest FY) | ₹5,366 Cr | ₹3,739 Cr |
| Net profit (latest FY) | ₹595 Cr | ₹0 Cr |
| Valuation | ||
| P/E | 31.1 | 469.5 |
| P/B | 3.38 | 3.69 |
| Dividend yield | 0.16% | 0.28% |
| Profitability | ||
| Return on equity | 10.9% | 0.8% |
| Net profit margin | 12.1% | 1.1% |
| Operating margin | 22.7% | 21.3% |
| Growth | ||
| Revenue growth (YoY) | +20.3% | -8.6% |
| Net profit growth (YoY) | +39.2% | — |
| Revenue CAGR (multi-year) | +10.6% | +11.3% |
| Financial health | ||
| Debt to equity | 0.09 | 0.01 |
| Momentum | ||
| 1-month return | -0.2% | +17.1% |
| 1-year return | +43.2% | -31.3% |
| 3-year CAGR | +30.1% | -14.4% |
| 5-year CAGR | +21.9% | -5.6% |
| 10-year CAGR | +22.7% | +5.1% |
| Distance from 52W high | -10.6% | -33.1% |
| Technicals | ||
| RSI (14) | 55 | 77 |
| Price vs 200-day avg | +8.6% | +5.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Granules India | Syngene International |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 8/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Granules India or Syngene International?
Granules India has a market cap of ₹22,182 Cr and Syngene International has a market cap of ₹17,936 Cr as of 13 Nov 2026.
Which has a lower P/E, Granules India or Syngene International?
Granules India has the lower P/E: Granules India trades at 31.1 and Syngene International at 469.5.
Which gave better returns in the last year, Granules India or Syngene International?
Granules India did better: Granules India returned +43.2% and Syngene International returned -31.3% over one year.
What is the difference between Granules India and Syngene International?
Both are NSE-listed companies in Healthcare. Granules India is about 1.2 times the size of Syngene International by market cap. In the latest financial year Granules India reported revenue of ₹5,366 Cr and Syngene International ₹3,739 Cr. Operating margin is 22.7% for Granules India and 21.3% for Syngene International. Debt to equity is 0.09 for Granules India and 0.01 for Syngene International.
Which is better, Granules India or Syngene International?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Granules India leads on 13 and Syngene International on 4. Granules India is ahead on size, valuation, profitability, momentum and technicals. Syngene International is ahead on financial health. On StoxGud's rules-based checklist Granules India scores 8/10 and Syngene International scores 3/10. This is information, not advice: consult a SEBI-registered adviser before investing.